Comparative Pharmacology
Head-to-head clinical analysis: CYMBALTA versus EFFEXOR XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYMBALTA versus EFFEXOR XR.
CYMBALTA vs EFFEXOR XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin and norepinephrine reuptake inhibitor (SNRI); increases extracellular levels of serotonin and norepinephrine by inhibiting their reuptake into presynaptic neurons.
Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI). It potently inhibits the reuptake of serotonin and norepinephrine, and weakly inhibits dopamine reuptake. It has no significant affinity for muscarinic, histaminergic, or alpha1-adrenergic receptors.
60 mg orally once daily, without regard to meals; some patients may benefit from a starting dose of 30 mg once daily for 1 week before increasing to 60 mg once daily.
75 mg orally once daily; may increase by 75 mg/day increments every 4-7 days to max 225 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 12 hours (range 8–17 hours); supports once-daily dosing with consistent drug levels.
Venlafaxine: 3-7 hours (short, requires extended-release formulation for once-daily dosing); active metabolite O-desmethylvenlafaxine: 9-13 hours (contributes to overall clinical effect). Steady-state achieved within 3 days.
Renal: approximately 70% as metabolites (duloxetine glucuronide conjugates and sulfate conjugates), 20% as unchanged drug in urine; fecal: approximately 20% as metabolites; biliary: minor contribution.
Renal: approximately 87% as metabolites (including venlafaxine, O-desmethylvenlafaxine, and other minor metabolites) and ≤5% as unchanged drug. Biliary/fecal: minimal (about 2%).
Category C
Category C
SNRI Antidepressant
SNRI Antidepressant